Volume Alert - PFE 30.60 Pfizer Inc $PFE Hit a hig
Post# of 47154
Posted On: 11/13/2014 11:58:49 AM
Volume Alert - PFE 30.60 Pfizer Inc $PFE Hit a high today of 30.60 Closing the day 10:30 at 30.60 +0.18 +0.59% With a day low of 30.46 and a total volume of 2,455,881.
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Novel Agreement Expands Access to Pfizer's Contraceptive, Sayana(R) Press, for Women Most in Need in the World's Poorest Countries
Business Wire - 57 mins ago
Pfizer Inc., the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) today announced an agreement that will expand access to Pfizer's injectable contraceptive, Sayana(R) Press (medroxyprogesterone acetate), for women most in need in 69 of the world's poorest countriesi. Through this collaboration of organizations from the public and private sectors, Sayana(R) Press will be sold for US $1 per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.
PFE: 30.46 (+0.04)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - 2 hrs 47 mins ago
PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), AZN: 74.50 (+0.24), BIND: 10.05 (+0.07)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.46 (+0.04), ABBV: 63.91 (+0.15)
Most active New York Stock Exchange-traded stocks
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
ZTS: 42.89 (+0.25), GE: 26.51 (-0.01), F: 14.95 (+0.37), S: 4.99 (-0.01), PFE: 30.46 (+0.04), BAC: 17.18 (-0.11), TWTR: 41.41 (-1.13), GNW: 9.16 (+0.36)
Final Glance: Pharmaceuticals companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.95 (+0.20), BAX: 72.05 (+0.72), PFE: 30.46 (+0.04), BMY: 57.82 (-0.79)
Pfizer's (PFE) Management Presents at Credit Suisse 2014 Healthcare Conference Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST
PFE: 30.46 (+0.04)
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 108.95 (+0.20), PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), AMGN: 159.97 (-1.96), MO: 49.55 (+0.22), CVX: 116.65 (-1.00)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.95 (+0.20), BAX: 72.05 (+0.72), PFE: 30.46 (+0.04), BMY: 57.82 (-0.79)
Ackman and a Former Protege Launch Campaign at Zoetis
at The Street - Wed Nov 12, 10:49AM CST
Investors will look for response from Zoetis on its investor day scheduled for Nov. 18.
ZTS: 42.89 (+0.25), PFE: 30.46 (+0.04)
Early Glance: Pharmaceuticals companies
AP - Wed Nov 12, 10:05AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.95 (+0.20), BAX: 72.03 (+0.70), PFE: 30.46 (+0.04), BMY: 57.82 (-0.79)
Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - Wed Nov 12, 10:04AM CST
ZTS: 42.89 (+0.25), T: 35.66 (+0.26), VRX: 132.93 (+1.84), FOSL: 110.02 (-2.46), BBT: 37.46 (-0.21), PFE: 30.46 (+0.04), KORS: 70.82 (-0.18), SUSQ: 13.08 (-0.04)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 42.89 (+0.25), AGN: 196.99 (+0.48), HLF: 37.70 (-0.11), VRX: 132.93 (+1.84), PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), LLY: 67.93 (+0.53)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.80 (-0.09), AGN: 196.99 (+0.48), ACT: 243.14 (+2.52), IRWD: 13.39 (-0.36), CBST: 72.35 (+0.04), PFE: 30.46 (+0.04)
Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 12, 7:03AM CST
Here at The Motley Fool, we sing the praises of Warren Buffett quite often -- and with good reason. Buffett, in a hair over 60 years, turned a small fortune of around $10,000 into a net worth of more than $70 billion as of this past Friday. Clearly,...
PFE: 30.46 (+0.04)
Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting
Business Wire - Wed Nov 12, 7:01AM CST
--Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus
PFE: 30.46 (+0.04)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.70 (+0.16), JNJ: 108.94 (+0.19), IDRA: 2.48 (-0.08), DERM: 15.93 (-0.32), MRK: 59.68 (+0.37), PFE: 30.46 (+0.04), AZN: 74.50 (+0.24), AMGN: 159.96 (-1.97), GSK: 45.73 (+0.11), HSP: 57.86 (-0.23), NVS: 94.50 (+1.84), CELG: 107.15 (-1.10)
Zoetis shares jump on investment by activist
By The Associated Press - AP - Tue Nov 11, 3:44PM CST
Zoetis Inc. shares jumped Tuesday on a report that activist investor William Ackman has taken a stake in the animal health company and could push for its sale.
ZTS: 42.89 (+0.25), PFE: 30.46 (+0.04)
Dow Index Dogs: 10% Bonus In 5 Lowest-Price, High-Yield Stocks
Fredrik Arnold - at Seeking Alpha - Tue Nov 11, 1:26PM CST
KO: 42.78 (+0.07), T: 35.66 (+0.26), GE: 26.50 (-0.02), PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), MCD: 95.53 (+0.20), PG: 89.27 (-0.21), CVX: 116.64 (-1.01), VZ: 50.96 (+0.14), CSCO: 25.69 (+0.58)
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Novel Agreement Expands Access to Pfizer's Contraceptive, Sayana(R) Press, for Women Most in Need in the World's Poorest Countries
Business Wire - 57 mins ago
Pfizer Inc., the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) today announced an agreement that will expand access to Pfizer's injectable contraceptive, Sayana(R) Press (medroxyprogesterone acetate), for women most in need in 69 of the world's poorest countriesi. Through this collaboration of organizations from the public and private sectors, Sayana(R) Press will be sold for US $1 per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.
PFE: 30.46 (+0.04)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - 2 hrs 47 mins ago
PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), AZN: 74.50 (+0.24), BIND: 10.05 (+0.07)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.46 (+0.04), ABBV: 63.91 (+0.15)
Most active New York Stock Exchange-traded stocks
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
ZTS: 42.89 (+0.25), GE: 26.51 (-0.01), F: 14.95 (+0.37), S: 4.99 (-0.01), PFE: 30.46 (+0.04), BAC: 17.18 (-0.11), TWTR: 41.41 (-1.13), GNW: 9.16 (+0.36)
Final Glance: Pharmaceuticals companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.95 (+0.20), BAX: 72.05 (+0.72), PFE: 30.46 (+0.04), BMY: 57.82 (-0.79)
Pfizer's (PFE) Management Presents at Credit Suisse 2014 Healthcare Conference Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST
PFE: 30.46 (+0.04)
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 108.95 (+0.20), PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), AMGN: 159.97 (-1.96), MO: 49.55 (+0.22), CVX: 116.65 (-1.00)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.95 (+0.20), BAX: 72.05 (+0.72), PFE: 30.46 (+0.04), BMY: 57.82 (-0.79)
Ackman and a Former Protege Launch Campaign at Zoetis
at The Street - Wed Nov 12, 10:49AM CST
Investors will look for response from Zoetis on its investor day scheduled for Nov. 18.
ZTS: 42.89 (+0.25), PFE: 30.46 (+0.04)
Early Glance: Pharmaceuticals companies
AP - Wed Nov 12, 10:05AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.95 (+0.20), BAX: 72.03 (+0.70), PFE: 30.46 (+0.04), BMY: 57.82 (-0.79)
Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - Wed Nov 12, 10:04AM CST
ZTS: 42.89 (+0.25), T: 35.66 (+0.26), VRX: 132.93 (+1.84), FOSL: 110.02 (-2.46), BBT: 37.46 (-0.21), PFE: 30.46 (+0.04), KORS: 70.82 (-0.18), SUSQ: 13.08 (-0.04)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 42.89 (+0.25), AGN: 196.99 (+0.48), HLF: 37.70 (-0.11), VRX: 132.93 (+1.84), PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), LLY: 67.93 (+0.53)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.80 (-0.09), AGN: 196.99 (+0.48), ACT: 243.14 (+2.52), IRWD: 13.39 (-0.36), CBST: 72.35 (+0.04), PFE: 30.46 (+0.04)
Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 12, 7:03AM CST
Here at The Motley Fool, we sing the praises of Warren Buffett quite often -- and with good reason. Buffett, in a hair over 60 years, turned a small fortune of around $10,000 into a net worth of more than $70 billion as of this past Friday. Clearly,...
PFE: 30.46 (+0.04)
Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting
Business Wire - Wed Nov 12, 7:01AM CST
--Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus
PFE: 30.46 (+0.04)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.70 (+0.16), JNJ: 108.94 (+0.19), IDRA: 2.48 (-0.08), DERM: 15.93 (-0.32), MRK: 59.68 (+0.37), PFE: 30.46 (+0.04), AZN: 74.50 (+0.24), AMGN: 159.96 (-1.97), GSK: 45.73 (+0.11), HSP: 57.86 (-0.23), NVS: 94.50 (+1.84), CELG: 107.15 (-1.10)
Zoetis shares jump on investment by activist
By The Associated Press - AP - Tue Nov 11, 3:44PM CST
Zoetis Inc. shares jumped Tuesday on a report that activist investor William Ackman has taken a stake in the animal health company and could push for its sale.
ZTS: 42.89 (+0.25), PFE: 30.46 (+0.04)
Dow Index Dogs: 10% Bonus In 5 Lowest-Price, High-Yield Stocks
Fredrik Arnold - at Seeking Alpha - Tue Nov 11, 1:26PM CST
KO: 42.78 (+0.07), T: 35.66 (+0.26), GE: 26.50 (-0.02), PFE: 30.46 (+0.04), MRK: 59.68 (+0.37), MCD: 95.53 (+0.20), PG: 89.27 (-0.21), CVX: 116.64 (-1.01), VZ: 50.96 (+0.14), CSCO: 25.69 (+0.58)
(0)
(0)